This study shows that tumor-derived PGRN provides protection against the immune attack that induces of T cell exclusion in the primary breast cancer, and it is potentially used as preclinical data that support the feasibility for targeting tumor-derived PGRN combined with immune checkpoint blocker anti-PD-1 for the treatment of breast cancer and provide a new idea for the immunotherapy of breast cancer. This evidence concerns the gene PDCD1 and breast carcinoma.